Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.

The present invention concerns the use of laminins and/or galectins as biomarker(s) for predicting the outcome of the treatment with oncolytic parvovirus H1 (H-1 PV) in a cancer patient.

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to the active site of carbonic anhydrase, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid, amide, ureido, or polyethylene glycol derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Provided are methods involving the assaying of a labeled cell suspension, e.g., to detect cancer-related cells, populations ON thereof and/or screen for metastatic cancer. Labeled cell suspensions may be assayed to detect whether a tumor infiltrating lymphocyte (TIL) population is present in a cellular suspension of a subject. Cancer-related cell populations of interest include, e.g., those expressing one or more markers, including where the markers are members of a marker panel. Markers assayed may vary depending on the context and may include protein markers, nucleic acid markers, cell cycle markers, DNA content markers, and the like. Useful markers include one or more immune checkpoint markers and/or one or more immune cell-type markers, including where the marker(s) assayed are part of one or more panels of markers. Also provided are methods of treating a subject for a neoplasia based on the outcome of an assay of a labeled cell suspension of sample from a subject. Kits for practicing the described methods are also provided.

The present invention relates to a method for predicting the prognosis of abreast cancer patient and, more particularly, to a method for predicting the prognosis of breast cancer by combining immune-related genes. The present invention is applicable to all breast cancer patients regardless of the breast cancer molecular subtype, and in addition, if the immune-related gene combination is used to predict the prognosis of breast cancer, as provided in the present invention, it is possible to predict the prognosis of a breast cancer patient without information on proliferation genes.

An antibody or an antigen-binding fragment thereof that binds to human CD38. The antibody or the antigen-binding fragment thereof can effectively bind to human CD38 and is applied to preparing a drug for treating diseases having strong CD38 expression (such as multiple myeloma), thereby having good prospects in clinical application.

The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

The present disclosure discloses an antibody combination for substituting a side scatter signal in mass cytometry hematologic tumor immunophenotyping, including a Lactoferrin antibody and a Lysozyme antibody. The present disclosure also discloses a gating method for mass cytometry hematologic tumor immunophenotyping. The present disclosure also discloses a kit for mass cytometry hematologic tumor immunophenotyping. According to the present disclosure, the Lactoferrin antibody and the Lysozyme antibody are used for the first time, are combined with a CD45 antibody for two-stage gating strategy, and are combined with a mass cytometer to substitute traditional flow cytometry CD45/SSC to distinguish mature granulocytes, monocytes, nucleated red blood cells, lymphocytes, primitive and juvenile cells, and abnormal cell subsets in bone marrow. Combined with the multi-parameter high-throughput characteristics of the mass cytometry, the present disclosure can improve the depth of the current hematologic tumor immunophenotyping.

The present disclosure relates generally to ex vivo expanded T cell populations suitable for use in adoptive immunotherapy. The disclosure also provides compositions and methods useful for preparing such ex vivo expanded T cell populations, as well as methods for the prevention and/or treatment of health conditions using the disclosed T cell populations.

Methods of determining suitability of a subject to be treated with a PD-1/PD-L1 based immunotherapy, comprising receiving a sample from the subject and determining HVEM levels in the sample, wherein expression of HVEM above a predetermined threshold indicates the subject is suitable to be treated by the immunotherapy or of determining suitability of a subject non-responsive to a PD-1/PD-L1 based immunotherapy to be treated by an HVEM based immunotherapy, comprising receiving a sample from the subject and determining T cell levels in the sample, wherein T cell levels above a predetermined threshold indicates the subject is suitable to be treated by the HVEM based immunotherapy are provided.